Project description
Imaging technology for assessment of patient immune status
Immunotherapy can effectively treat a number of serious conditions such as cancer and inflammatory diseases but a personalised approach is key. Blood and tissue markers coupled with non-invasive imaging could aid in assessing immune status in vivo, but this option has barely been explored. To this end, the EU-funded project will develop new immunotracers for imaging specific immune cell subsets, and then validate them in relevant disease models. The goal is to transfer them to manufacturing and then conduct smart clinical trials. This international multi-disciplinary consortium will work on optimising molecular imaging techniques for assessing patient immune status via immunotracers and developing personalised immunotherapeutic drugs.
Objective
Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers.
To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions.
To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1081 HV Amsterdam
Netherlands
See on map
Participants (24)
72074 Tuebingen
See on map
CB2 1TN Cambridge
See on map
48149 MUENSTER
See on map
1050 Bruxelles / Brussel
See on map
9052 ZWIJNAARDE - GENT
See on map
9713 GZ Groningen
See on map
08035 Barcelona
See on map
08035 Barcelona
See on map
75015 PARIS 15
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
Participation ended
91190 Gif-Sur-Yvette
See on map
431 53 MOLNDAL
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3521 AL Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2289 DC Rijswijk
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
2289 DC Rijswijk
See on map
1016 XX Amsterdam
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
1210 Bruxelles / Brussel
See on map
4070 Basel
See on map
51373 Leverkusen
See on map
2340 Beerse
See on map
4056 Basel
See on map
CT13 9NJ Sandwich
See on map
90301 Inglewood Ca
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
WC2B 4AE London
See on map
8152 Glattpark
See on map